Clinical Trials
25 trialsNCT04557059 2026-06-05
PRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Phase 3 Active not recruiting
NCT04892173 2026-06-05
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Johnson & Johnson Enterprise Innovation Inc.
Phase 3 Recruiting
NCT06667908 2026-06-05
CONVERGE
Johnson & Johnson Enterprise Innovation Inc.
Phase 2 Recruiting
NCT05765812 2026-05-28
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT05109728 2026-05-22
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT04210115 2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06116786 2026-05-08
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Recruiting
NCT03491683 2026-05-04
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT05009069 2026-04-21
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
NCT05124912 2026-02-20
REMASTer: REcurrent Brain Metastases After SRS Trial
Monteris Medical
Phase NA Recruiting
NCT03407144 2026-02-19
MK-3475-667
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT05491317 2026-02-19
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Genmab
Phase 1/2 Terminated
NCT06459869 2026-02-17
FORTRESS
Akamis Bio
Phase 1 Recruiting
NCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT03040999 2026-02-04
KEYNOTE-412
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04504942 2026-01-23
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
CytoDyn, Inc.
Phase 2 Completed
NCT03423628 2025-12-22
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
Phase 1 Recruiting
NCT04373785 2025-10-21
NG101m Adjuvant Therapy in Glioblastoma Patients
NeuGATE Theranostics
Phase 1/2 Not yet recruiting
NCT07192588 2025-09-25
GuARD
Graegis Pharmaceuticals Ltd
Phase 2 Active not recruiting
NCT03444714 2025-09-15
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
Coordination Pharmaceuticals, Inc.
Phase 1 Completed
NCT01107522 2025-09-09
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Tactical Therapeutics, Inc.
Phase 1 Unknown
NCT03725059 2025-07-11
KEYNOTE-756
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04121455 2025-06-25
GLORIA
TME Pharma AG
Phase 1/2 Active not recruiting
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed